Amgen faces Delaware patent verdict, shares under legal scrutiny

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-23, 07:04.

Amgen (US0311621009) has moved back into the spotlight on the NASDAQ after a Delaware federal jury found willful infringement of an antibody patent owned by Harbour BioMed and awarded more than 20 million US dollars in damages, according to a recent analyst commentary based on court filings and market data.A Yahoo Finance analysis summarizing the verdict highlights the potential for enhanced damages and a reassessment of Amgen’s intellectual property risk.

What the verdict covers

According to the Yahoo Finance analysis drawing on Delaware court records, the jury in June 2026 concluded that Amgen and a subsidiary willfully infringed Harbour BioMed’s so?called Grosveld patent relating to antibody technology, awarding exactly 20,203,704 US dollars in damages to Harbour BioMed.The same report notes that under US law the court may consider increasing the award, potentially up to three times, because the infringement was found to be willful.

The case centers on antibody development platforms that can be used to generate therapeutic candidates, a field where Amgen competes with large-cap biotech peers such as AbbVie and Bristol Myers Squibb in the US market.Analyst pages for Amgen on Yahoo Finance point out that legal disputes over platform technologies can affect both collaboration economics and long-term pipeline valuations.

How analysts frame the risk

In the wake of the Delaware ruling, several Wall Street research summaries collected by data providers report that the majority of analysts still rate Amgen as a Buy or Overweight, but many explicitly flag litigation and patent challenges as a key risk factor for the stock.MarketWatch consensus data on Amgen show an average 12?month price target in the low 300?dollar range, reflecting expectations for stable earnings from mature therapies alongside contributions from newer products.

Data from one widely followed consensus service indicate that more than 20 covering analysts publish formal recommendations on Amgen, with a clear majority in the positive camp and only a small minority rating the shares at Hold or Sell.A MarketScreener consensus overview lists double?digit expected earnings per share for the current fiscal year, underpinning the company’s status as a large, cash?generative biotech in the S&P 500.

The therapies behind the stock

Amgen generates most of its revenue with biologic drugs in oncology, inflammation and bone health, including long?standing products such as the neutropenia treatment Neulasta and the osteoporosis therapy Prolia, alongside newer cardiovascular offerings like the PCSK9 inhibitor Repatha that expand its presence in chronic disease care.

Where the shares trade today

The Amgen shares (US0311621009) most recently traded on the NASDAQ at around 305 US dollars per share, based on the latest available quote data for US trading hours.

This article is for informational purposes only and does not constitute investment advice, investment recommendation or an offer or solicitation to buy or sell any financial instrument. Historical data and analyst estimates are not a reliable indicator of future performance.